z-logo
open-access-imgOpen Access
CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Author(s) -
Mark J. Smyth,
Michele W.L. Teng,
Jeremy B. Swann,
Konstantinos Kyparissoudis,
Dale I. Godfrey,
Yoshihiro Hayakawa
Publication year - 2006
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.176.3.1582
Subject(s) - nkg2d , cytolysis , il 2 receptor , interleukin 21 , cancer immunotherapy , cancer research , immunotherapy , immune system , cell , natural killer cell , biology , microbiology and biotechnology , t cell , immunology , cytotoxicity , in vitro , biochemistry
CD4+CD25+ regulatory T cells (Treg) that suppress T cell-mediated immune responses may also regulate other arms of an effective immune response. In particular, in this study we show that Treg directly inhibit NKG2D-mediated NK cell cytotoxicity in vitro and in vivo, effectively suppressing NK cell-mediated tumor rejection. In vitro, Treg were shown to inhibit NKG2D-mediated cytolysis largely by a TGF-beta-dependent mechanism and independently of IL-10. Adoptively transferred Treg suppressed NK cell antimetastatic function in RAG-1-deficient mice. Depletion of Treg before NK cell activation via NKG2D and the activating IL-12 cytokine, dramatically enhanced NK cell-mediated suppression of tumor growth and metastases. Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom